Navigation Links
Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients
Date:9/22/2010

h a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: http://www.astrazeneca.com.

About Rigel

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune, muscle and metabolic diseases. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib (R788), an oral syk inhibitor that is expected to enter phase III clinical trials for rheumatoid arthritis in 2010, and R343, an inhaled syk inhibitor that is in clinical trials for asthma.

Rigel Forward-Looking Statements

This press release contains "forward-looking" statements, including, without limitation, statements related to plans to pursue further clinical development of R788 (fostamatinib), including the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "estimate," "anticipate" and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with the timing and success
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. More Evidence Published That Epidemics of Childhood Obesity, Type 2 Diabetes and Metabolic Syndrome are Linked to Immunization
3. Clinical Study of Intermezzo(R) for the Treatment of Middle of the Night Awakening Published in SLEEP
4. Wound Management Technologies, Inc. Announces a Published Case Study
5. Technique for Creating Authentic Rat Embryonic Stem Cells Published in Cell
6. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
7. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
8. Universal Bioenergy, Inc. Expressly Disclaims Any Responsibility for the Content, Accuracy of Information, and Quality of Information Regarding Universal Published by Any Third-Party and Being Disseminated on the Internet
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Pre-Clinical Data on CEA-specific BiTE Antibody Published in Journal of Immunotherapy Demonstrate Potent Control of Tumor Growth
11. Life sticks: UC San Diego bioengineers sticky insights published in journal Science
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 Why did Stephen Hawking become ... so instantly recognizable? Why have they become icons to ... author Hilton Ratcliffe seeks out the answers to those ... to do with science. In " Stephen Hawking Smoked ... 21, 2014), Ratcliffe puts it plainly: , “It ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
(Date:11/21/2014)... , Nov. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... nine month periods ended September 30, 2014.  Biorem,s complete 2014 third ... www.sedar.com ). Financial Summary:Three-months ended September 30, ... per share data) , 2014 , 2013 ... 2,282 , 5,281 , 6,715 , ...
(Date:11/18/2014)... 2014 Cirrascale Corporation ®, ... and rackmount computing infrastructure, today announced it will ... throughout its GPU-enabled blade server and high-performance workstation ... latest proprietary 80-lane Gen3 PCIe switch-enabled risers, the ... K80 dual-GPU accelerator cards in a single blade, ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... Decision Biomarkers Inc, a leading,developer of protein ... announced the formation of a Scientific Advisory Board,consisting ... of biomarker and clinical research. The Scientific Advisory ... -- Daniel W. Chan, Ph.D., Director of the ...
... Bionovo, Inc.,(Nasdaq: BNVI ), a pharmaceutical company focused on ... of women,s health and,cancer, announced that Isaac Cohen, Chairman and CEO ... 20th Annual Piper Jaffray Health,Care Conference at 8 a.m. EST on ... York Palace Hotel in New York City. , ...
... Dec. 2 Associated Cardiovascular Associates,(ACC), a ... locations in,Southern New Jersey, today announced that ... records and Sage Intergy practice management solution. ... more than 30,000 patients,annually, will deploy the ...
Cached Biology Technology:Decision Biomarkers Inc Announces Formation of Scientific Advisory Board 2Bionovo to Present at the Piper Jaffray Healthcare Conference 2Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship 2Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship 3Associated Cardiovascular Consultants Selects Sage Intergy EHR to Enhance Quality, Clinical Trial Research and Physician-Patient Relationship 4
(Date:11/18/2014)...  The Secure Identity & Biometrics Association (SIBA) ... the formation of The Airport Entry and Exit ... and Biometric Entry and Exit Solutions Framework for ... from BORDERPOL, the international non-profit organization that works ... regarding border security, traveler and migration systems. ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a ... that its U.are.U ® fingerprint readers have been ... in Central Mexico . The bakery ... to eliminate payroll issues caused by employees clocking in ... the U.are.U fingerprint readers, Montparnasse relied on paper timecards ...
(Date:11/7/2014)... CORAL SPRINGS, Florida , November 6, 2014 ... improved secure authentication for better mobile security revolutionizing online transactions. ... NXTD ), Alibaba Holdings Ltd. (NYSE: BABA ), ... MSFT ), eBay Inc. (NASDAQ: EBAY ... (NASDAQ: NXTD and NXTDW), a biometric authentication ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... (August 30, 2007) Saudi Arabias King Abdullah University ... Institute of Technology, Bombay (IIT Bombay) , signed ... to work together to foster world-class programs that will ... fundamental and applied chemical sciences for the benefit of ...
... the odds a teenage girl will begin smoking, a University ... the dieting and smoking practices of 8,000 adolescents, did not ... likely than girls to diet, according to findings released Friday ... a significant predictor of initiation of regular smoking among females, ...
... Salvador in the September issue of BioScience presents novel ... monies sent to family members by emigrants have transformed ... B. Hecht and Sassan S. Saatchi, employed socioeconomic data, ... in the area of El Salvador covered by both ...
Cached Biology News:Saudi Arabia's KAUST and IIT, Bombay to Collaborate on Scientific Research 2Girls who begin dieting twice as likely to start smoking 2Girls who begin dieting twice as likely to start smoking 3Population movements and money remittances spur forest regrowth 2
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Rad51B...
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
Biology Products: